www.ThePharmaJournal.com

The Pharma Innovation

ISSN (E): 2277- 7695
ISSN (P): 2349-8242
NAAS Rating 2017: 5.03
TPI 2017; 6(10): 425-430

www.thepharmajournal.com
Received: 13-09-2017
Accepted: 14-10-2017

Pawan Jalwal
Research Scholar, Department of Pharmaceutical Sciences, OPJS University, Churu, Rajesthan, India

Anil Middha
Director, Faculty of Pharmaceutical Sciences, OPJS University, Churu, Rajesthan, India

Correspondence
Pawan Jalwal
Research Scholar, Department of Pharmaceutical Sciences, OPJS University, Churu, Rajesthan, India

Design, development and evaluation of floating tablet of famotidine for the treatment of duodenal ulcer

Pawan Jalwal and Anil Middha

Abstract
Famotidine is histamine H_2 receptor antagonist in treating gastric ulcer, duodenal ulcer, Zollinger Ellison syndrome, gastroesophegal reflux disease and erosive esophagitis. It inhibits acid production by reversibly competing with histamine for binding to H_2 receptors on the basolateral membrane of parietal cells. It competitively inhibits histamine action at all H_2 receptors but their main clinical use is as inhibition of gastric acid secretion. It inhibited histamine stimulation and gastrin stimulated acid secretion. It decreases both basal and food stimulated acid secretion by 90% or more, but promote healing of duodenal ulcer. The swelling of the polymers used (HPMC K15M, Ethyl cellulose, Xanthan Gum) were determined by water uptake of the tablet. The percent swelling of the tablet was determined for 12 h at different time intervals. In present work an attempt was made to prepare the Floating Tablet of Famotidine using different polymers by wet granulation and direct compression method with Lactose, DCP and MCC as diluents, citric acid and Sodium bicarbonate as gas generating agent.

Keywords: famotidine, zollinger ellison syndrome, duodenal ulcer, gastrin, histamine

Introduction
Famotidine is histamine H_2 receptor antagonist in treating gastric ulcer, duodenal ulcer, Zollinger Ellison syndrome, gastroesophegal reflux disease and erosive esophagitis. It inhibits acid production by reversibly competing with histamine for binding to H_2 receptors on the basolateral membrane of parietal cells. It competitively inhibits histamine action at all H_2 receptors but their main clinical use is as inhibition of gastric acid secretion. It inhibited histamine stimulation and gastrin stimulated acid secretion. It decreases both basal and food stimulated acid secretion by 90% or more, but promote healing of duodenal ulcer. The chemical name of famotidine is Propanimidamide, N-(aminosulfonyl)-3 [[[2-[(diaminomethylene)-amino]-4- thiazolyl] methyl] thio] - [1-amino-3- [[[2-[(diaminomethylene) amino]-4- [thiazolyl]-methyl] thio] propylidene] sulfamide. The molecular formula and molecular weight of famotidine are $C_8H_{15}N_7O_2S_3$ and 337.445 respectively. It is a white or Yellowish-white, crystalline powder or crystals having melting point is 163-169ºC. It is freely Soluble in Dimethyl Formamide and in Glacial Acetic Acid, slightly soluble in Methyl Alcohol, very slightly soluble in water and in Dehydrated Alcohol, Practically insoluble in ether and in Ethyl Acetate. It is preserve in well closed container, Protected from light. The structure of famotidine is given below (figure 1)



Fig 1: The structure of Famotidine

The major therapeutic use of famotidine is promoting healing for gastric and duodenal ulcer, treatment of uncomplicated Gastroesophageal reflux disease (GERD) and for prophylactic treatment of stress ulcer. In addition, it employed in combination with antibiotics to treat infection with Helicobacter pylori i.e. in treatment of Gastritis.

Pharmacokinetics

Table 1: Pharmacokinetics of Famotidine

Bioavailability	40-45%
Plasma Half Life	2.5h-3.5hrs.
Plasma Protein Binding	15- 20%
Peak Plasma Concentration (C_{max})	1- 3 hours
Excretion	Renal Excretion (65-70%) Metabolic Excretion (30-35%)
Renal Clearance	250-450ml/min
Drug Interaction	It does not inhibit hepatic microsomal enzyme CYTP450 system and hence does not interact with drugs which are substrate for CYTP450 systems like Warfarin, Pheytoin, Quinidine, Caffiene etc. It does not block androgen receptors and do not cause Gynaecomastia and impotence like Cimetidine.

Material and methods

Famotidine was received as a gift sample from Belco Pharma, Bahadurgarh, Haryana, India. Hypromellose (HPMC), Xanthan Gum, Ethyl Cellulose, Microcrystalline Cellulose, and Dibasic Calcium Phosphate were received as a gift from Central Drug House, Mumbai. Povidone and HCl were received as a gift sample from Merck Specialities Pvt Ltd, Mumbai. Isopropyl Alcohol was purchased from Nice Chemicals Pvt. Ltd, Cochin. Magnesium stearate and talc were perchased as a gift from Qualikems Fine Chemicals Pvt. Ltd, Delhi. Lactose was purchased from Central Drug House (P) Ltd. New Delhi, India. All other ingredients used were of analytical grade.

Experimental methods

Preparation of Floating Tablets of Famotidine

The composition of different formulations of Famotidine floating tablets was shown in table 2. The ingredients were weighed accurately and mixed thoroughly. Tablets of Famotidine were prepared by direct compression & wet compression method and their release profiles were compared to select the manufacturing process for further studies.

Selection of manufacturing process

Batches were prepared with HPMC K15M using wet granulation method and direct compression method and their release profiles were compared. Formula is given in Table 2.

Table 2: Formulation of Famotidine using HPMC K15M with direct compression and wet granulation methods

Batch No.	**P1 (Wet Granulation)**	**P2 (Direct Compression)**
Ingredients Name	mg/tab	mg/tab
Famotidine	80	80
HPMC K15M	90	90
Sodium bicarbonate	70	70
Citric Acid	30	30
Lactose	109	-
Microcrystalline Cellulose	-	124
Povidone	15	-
Isopropyl Alcohol	q.s.	-
Magnesium Stearate	3	3
Talc	3	3
Total	400	400

Formulation of batches with different ratio of Sodium bicarbonate and Citric acid

Batches were prepared with HPMC K15M using wet granulation method to select the proportion of Sodium bicarbonate and Citric Acid and their release profiles were compared. Formula is given in Table 3

Table 3: Formulation of batch with different ratio of Sodium bicarbonate and Citric acid

Batch No.	**P1**	**P3**	**P4**
Ingredients	**mg/tab**	**mg/tab**	**Mg/tab**
Famotidine	80	80	80
HPMC K15M	90	90	90
Sodium bicarbonate	70	80	90
Citric Acid	30	20	10
Lactose	109	109	109
Povidone	15	15	15
Isopropyl Alcohol	q.s.	q.s.	q.s.
Talc	3	3	3
Magnesium Stearate	3	3	3
Total	400	400	400

Preparation of trial batches with different polymers with different concentration

Formulation batches were prepared using different polymers (HPMC K15M, Xanthan gum, and Ethyl Cellulose). Formula is given in Table 4

Table 4: Formulation of different batches with different polymer concentration

Batch No.	P4	P5	P6	P7	P8	P9	P10
Ingredients	**mg/tab**	**mg/tab**	**mg/tab**	**mg/tab**	**Mg/tab**	**mg/tab**	**mg/tab**
Famotidine	80	80	80	80	80	80	80
HPMC K15M	90	110	130	90	90	90	90
Ethyl Cellulose	-	-	-	-	-	25	40
Xanthan Gum	-	-	-	25	40	-	-
Sodium bicarbonate	90	90	90	90	90	90	90
Citric Acid	10	10	10	10	10	10	10
DCP	-	-	-	84	69	84	-
Lactose	109	89	69	-	-	-	69
Povidone	15	15	15	15	15	15	15
Isopropyl Alcohol	q.s.	q.s.	q.s.	q.s.	q.s.	q.s.	q.s.
Talc	3	3	3	3	3	3	3
Magesium Stearate	3	3	3	3	3	3	3
Total	400	400	400	400	400	400	400

Effect of various diluents with their elastic or plastic properties:

Formulations were prepared using different diluents such as dibasic calcium phosphate and Lactose and compared to select the best diluent for further formulations. Formula is given in Table 5.

Table 5: Formulation of Famotidine by using different diluents with their elastic or plastic properties

Batch No.	P8	P11
Ingredients	**mg/tab**	**mg/tab**
Famotidine	80	80
HPMC K15M	90	90
Xanthan Gum	40	40
Sodium bicarbonate	90	90
Citric Acid	10	10
Lactose	69	-
DCP	-	69
Povidone	15	15
Isopropyl Alcohol	q.s.	q.s.
Talc	3	3
Magnesium Stearate	3	3
Total	400	400

In – Vitro evaluation

Precompression evaluation of Famotidine are given below

Table 6: Results of flow properties of granules

Batch No.	Bulk Density	Tapped Density	Angle of Repose	Hausner's ratio	Carr's index
P1	0.392	0.542	37.8,(fair)	1.38,(poor)	27.67,(poor)
P2	0.388	0.573	35.6, (fair)	1.47, (poor)	32.28, (poor)
P3	0.390	0.593	38.2, (fair)	1.52, (poor)	34.23, (poor)
P4	0.398	0.485	39.4, (fair)	1.21, (fair)	17.9, (fair)
P5	0.372	0.492	36.3, (fair)	1.32, (passable)	24.3, (passable)
P6	0.380	0.511	34.2, (good)	1.34, (passable)	25.6, (poor)
P7	0.386	0.495	37.3, (fair)	1.28, (passable)	22.02, (passable)
P8	0.394	0.482	33.5, (good)	1.22, (fair)	18.25, (fair)
P9	0.381	0.493	33.8, (good)	1.29, (passable)	22.7, (passable)
P10	0.376	0.532	36.2, (fair)	1.41, (poor)	29.32, (poor)
P11	0.385	0.480	37.7, (fair)	1.24, (fair)	19.7, (fair)

Evaluation of colon targeted matrix tablets

Table 7: Results of evaluation of parameters of tablets from different batches

Batch No.	Average weight(mg)	Thickness (mm)	Friability %	Hardness (kp)	Assay	Floating lag time (sec)s	Floating Duration (h)
P1	403	3.7	0.04	5	97.62	120	24 h
P2	398	4.2	0.06	6	98.87	135	24 h
P3	402.3	4.0	0.03	4	97.37	110	24 h
P4	399	3.8	0.06	6	99.65	90	24 h
P5	397	3.5	0.02	5	101.25	120	24 h
P6	401	3.6	0.07	6	98.72	240	24 h
P7	399	3.7	0.05	6	99.56	90	24 h
P8	399.6	3.8	0.03	5	101.12	60	24 h
P9	401	4.2	0.01	4	97.89	40	24 h
P10	402	3.5	0.04	5	102.67	120	24 h
P11	401.3	3.7	0.02	4	98.52	30	24 h

Table 8: Results of swelling index

Time (hr)	P3	P4	P5	P6	P7	P8	P9	P10	P11
1	52.11	55.47	54.87	47.79	59.66	60.65	57.32	59.21	60.65
2	59.17	62.20	59.60	56.89	67.25	69.52	62.58	69.52	72.56
3	67.81	66.54	66.03	67.08	72.44	76.12	67.96	75.01	79.32
4	75.63	79.28	79.8	75.44	78.32	80.01	77.63	80.35	88.01
5	86.06	88.06	87.70	86.66	83.05	88.47	84.01	86.22	95.09
6	-	96.50	96.80	95.05	89.12	93.94	89.52	90.56	100.51
7	-	-	115.02	109.44	93.26	98.20	95.02	96.04	106.84
8	-	-	125.54	116.6	99.54	106.21	103.12	100.55	111.36
9	-	-	-	126.52	108.56	112.05	109.75	106.51	119.20
10	-	-	-	128.60	118.62	120.61	117.26	110.24	124.25
11	-	-	-	-	-	125.41	-	123.42	129.05
12	-	-	-	-	-	129.50	-	-	131.20



Fig 2: Swelling indices of various batches Vs. Time

Table 9: Release profiles of formulations using different polymers in different concentrations

Time (hr)	% Drug release						
	P4	P5	P6	P7	P8	P9	P10
1	52.1	25.27	22.14	26.14	25.62	26.14	29.50
2	65.7	40.67	40.32	34.21	32.32	33.37	38.11
3	76.9	49.90	46.71	45.58	48.66	47.06	45.16
4	85.4	60.09	58.32	48.50	59.47	56.49	58.17
5	93.7	68.99	68.54	52.31	65.24	60.21	63.25
6	100.7	78.21	75.42	62.91	69.89	68.37	68.71
7	-	87.44	85.46	69.40	76.27	78.83	74.21
8	-	98.55	90.50	75.30	82.60	89.40	77.65
9	-	-	95.63	85.40	89.21	93.20	88.80
10	-	-	99.50	92.13	93.12	99.93	97.40
11	-	-	-	99.83	98.56	-	105.51
12	-	-	-	-	103.36	-	-



Fig 3: Dissolution profile of formulations with different Polymers

Summary
Gastric ulcer, one of the most widespread, is believed to be due to an imbalance between aggressive and protective factors. The gastric mucosa is continuously exposed to potentially injurious agents such as acid, pepsin, bile acids, food ingredients, bacterial products (*Helicobacter pylori*) and drugs. These agents have been implicated in the pathogenesis of gastric ulcer, including enhanced gastric acid and pepsin secretion, inhibition of prostaglandin synthesis and cell proliferation growth, diminished gastric blood flow and gastric motility. Drug treatment of peptic ulcers is targeted at either counteracting aggressive factors (acid, pepsin, active oxidants, platelet aggravating factor "PAF", leukotrienes, endothelins, bile or exogenous factors including NSAIDs) or stimulating the mucosal defenses (mucus, bicarbonate, normal blood flow, prostaglandins (PG), nitric oxide). The goals of treating peptic ulcer disease are to relieve pain, heal the ulcer and prevent ulcer recurrence.
In present work an attempt was made to prepare the Floating Tablet of Famotidine using different polymers by wet granulation and direct compression method with Lactose, DCP and MCC as diluents, citric acid and Sodium bicarbonate as gas generating agent.
It was found that wet granulation method facilitated greater efficiency in controlling Famotidine release behavior from the matrices. Hence, all further formulations were prepared with wet granulation technique. FTIR studies shows that there was no incompatibility between drug, polymer and co-excipients. All the prepared formulations were evaluated for hardness, friability, uniformity of weight, thickness, in vitro buoyancy study, assay and in vitro release. Batches were prepared by HPMC and HPMC K15M+ EC, HPMC K15M+Xanthum gum. Ratio of polymers in formulation played major role in controlling the release rate of Famotidine, which is evident from the prolongation in release of Famotidine with HPMC: Xanthan gum. Concentration of sodium bicarbonate and citric acid affect the floating lag time and the entire formulation float up to 24 hours. Effect of diluent on drug release was also studied by comparing lactose and dibasic calcium phosphate. Dibasic calcium phosphate had maximum retarding capacity followed by lactose. The release kinetics of all the batches were carried out and it was found final batch followed Higuchi kinetic model. The optimized formulation has drug release profile up to 12 hours.

Conclusion
- The absorbance maxima of Famotidine were found as 265 nm which was selected for UV analysis.
- The physical compatibility study at 40ºC/75% RH showed that Famotidine and excipients used found to be physically compatible.
- FTIR spectra data showed that Famotidine and excipients used found to be compatible.
- Melting point of Famotidine was found to be 165ºC.
- Formulation was prepared with two processes i.e. direct compression and wet granulation; it was found that wet granulation method facilitated greater efficiency in controlling Famotidine release behaviour from the matrices as compared to direct compression.
- Characterization of granules prepared by selected manufacturing processes like bulk density, tapped density, Carr's index, Hausner's ratio, Angle of repose was done and found to have good flow and compressibility.
- The tablets prepared were found to be within the limits with respect to hardness, average weight, %friability and thickness.
- From the different polymers used in polymer selection batches, combination of HPMC and Xanthum gum were found to be satisfactory.
- Dibasic calcium phosphate was found to be the best diluent in controlling the release rate of drug and thus helps in extending the release profile.
- Under the study of kinetic models, five models have been studied namely Zero Order, First Order, Higuchi, Hixon-Crowell, Korsmeyer-Peppas model. It was found that the drug release model of final batch followed Higuchi kinetic model (having maximum R^2 value of 0.9966).

References
1. Chien YW. Oral drug delivery and delivery systems, Fundamentals of Rate Controlled Drug Delivery. In: Novel Drug Delivery Systems. New York: Marcel Dekker Inc, 1992, 43-137.
2. Banker GS, Anderson NR. Tablets: The theory and practice of industrial pharmacy. Lachman L, Lieberman HA, Kanig JL. Eds. 3rd; Varghese Pub. House: Bombay, 2003, 293-294.
3. Das NG, Das SK. Controlled-release of oral dosage forms. Pharm. Technol. 2010; 2(2):90-96.
4. Brahamanker DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics. Vallabh Prakashan, 2004, 335.
5. Robinson JR, Vincent HL. Controlled drug delivery: Fundamentals and applications, New York: Marcel Dekker Inc. 2002; 29:3-61.
6. Patil JM, Hirlekar RS, Gide PS, Kadam VJ. Trends in Floating Drug Delivery Systems. J Scientific & Industrial Res. 2006; 65:11-21.
7. Etyan AK, Eran L, Michel F. Hoffman A. Expandable gastroretentive dosage forms. J Cont. Rel 2003; 909:143-162.
8. Shiva Kumar HG, Vishakante Gowda D, Kumar Pramod TM. Floating Controlled Drug Delivery System for Prolonged Gastric Residence: A Review. Indian J pharm. Educ 2004; 38(4):172-179
9. Jain NK. Pharmaceutical product development. 2nd Ed. Bangalore & New Delhi: CBS publisher, 2004, 40-45.
10. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev. 1998; 34:191-219.
11. Srivastav M, Prabhakar B, Omray A. Extended Release Tablet Technologies- Matrix, Melt Granulation and Multiparticulates: An Overview. International Journal of Universal Pharmacy and Life Sciences. 2011; 1(2):331-354.
12. Sampath KP, Bhownik D, Chandira M, Tripathi KK. Innovations in Sustained Release Drug Delivery System and its Market Opportunities. Journal of Chemical and Pharmaceutical Research. 2010; 2(1):349-360.
13. Ansel HC, Allen LV, Popovich NC, Pharmaceutical dosage forms and drug delivery systems, 7th Ed. Lippincott Williams and Wilkins; Baltimore, 2000, 231-240.
14. Jayanthi B, Manna PK, Madhusudhan S, Mohanta GP, Manavalan R. Oral Extended Release Product: An Overview. Applied Journal of Pharmaceutical Science. 2011; 1(2):50-55.
15. Deshpande AA, Shah NH, Christoper TR, Malik W.

Development of Novel Controlled Release System for Gastric Retention. Pharm. Res 1997; 14:815-819.
16. Yeole PG, Khan S, Patel VF. Floating Drug Delivery System: Need and Development. Ind. J Pharm. Sci. 2005; 67:265-272.
17. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery system: A Review. AAPS Pharm Sci. Tech. 2005; 6(3):E372-E373.
18. Shivakumar HG, Vishakante GD, Kumar Pramod TM. Floating Controlled Drug Delivery System for Prolonged Gastric Residence: A Review. Indian J pharm. Educ. 2004; 38(4):172-179.
19. Narang N. An updated review on: Floating Drug Delivery system; Int. Journal of Applied Pharmaceutics. 2011; 3(1):1-7.
20. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel compositions. J Control Release. 2000; 65:73-82.
21. Arunachalam A, Karthikeyan M, Konam K, Pottabathula HP, Sethuraman S, Ashutoshkumar S, Manidipa S. Floating Drug Delivery System: A Review; Int. Jounral of Res. Pharm. Sci. 2011; 2(1):76-83.
22. Saha SH, Patel JK, Pundarikakshudu N, Patel NV. An Overview of Gastroretentive floating drug Delivery system. Asian Journal of Pharmaceutical Sciences. 2009; 4(1):65-80.
23. Nayak AK, Maji R, Das B. Gastroretentive Drug Delivery System: A Overview. Asian Journal of Pharmaceutical and Clinical Research. 2010; 3(1):2-10.
24. Sanjay S, Joshi V, Barpete KP, Gastroretentive Drug Delivery System: Current Approaches. Joural of Pharmacy Research. 2009; 2(5):881-886.
25. Jamil F, Kumar S, Sharma S, Vishvakarma P., Singh L. Review on Stomach Specific Drug Delivery System: Development and Evaluation. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011; 2(4):1427-1433.
26. Surana AS, Kotecha RK. An overview on various approaches to oral controlled drug delivery system via gastroretention. Int J Pharm Sci Review and Res. 2010; 2(2):68-72.
27. Mathur P, Saroha S, Syan N, Verma S, Nanda S, Valecha V. An overview on recent advancements and developments in gastroretentive buoyant drug delivery system. Pelagia Research Library. 2011; 2(1):161-169.
28. Gangadharappa HV, Kumar Pramod TM, Kumar Shiva HG. Gastric Floating Drug delivery System: A Review. Indian J Pharm. Educ. 2007; 41(4):295-304.
29. Vanshiv DS, Joshi PH, Sherje A, Phale AAS, Dhat PS. Gastroretentive Drug Delivery System: Review. Journal of Pharmacy Research. 2009; 2(12):1879-1885.
30. Jain NK. Pharmaceutical product development. 2nd Ed. Bangalore & New Delhi: CBS publisher. 2004, 40-45.